Psychiatry | Page 21 of 61 | Links Medicus Content Curation & Alerts in Medicine

RCT: 10 to 25 mg/day agomelatine resulted in an improvement versus placebo in CDRS-R raw score of 4·22 (0·63–7·82) at 12 weeks in C&A with MDD, with a similar effect for fluoxetine. The overall effect was confirmed in adolescents, but not in children https://t.co/keecz57fQw

— P𝘧OL (@psychopharmacol) December 23, 2021

Study Commentary | Diagnostic labels in mental illness: helpful or harmful?

2 Feb, 2022 | 08:10h | UTC

Diagnostic labels: helpful or harmful? – The Mental Elf

Original Study: How does diagnostic labelling affect social responses to people with mental illness? A systematic review of experimental studies using vignette-based designs – Journal of Mental Health

Cohort Study: Association of preeclampsia and perinatal complications with offspring neurodevelopmental and psychiatric disorders.

30 Jan, 2022 | 13:51h | UTC

Association of Preeclampsia and Perinatal Complications With Offspring Neurodevelopmental and Psychiatric Disorders – JAMA Network Open

Cohort study: Among patients who survived ICU treatment for COVID-19, 75% still reported physical, mental, or cognitive symptoms after 1 year.

26 Jan, 2022 | 02:28h | UTC

Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19 – JAMA

Commentaries:

75% of COVID ICU survivors have physical symptoms 1 year on – CIDRAP

Majority of COVID-19 survivors experience health problems one-year post ICU admission – News Medical

Guidelines on Screen Time and Digital Wellness in Infants, Children and Adolescents – “children below 2 years age should not be exposed to any type of screen, whereas exposure should be limited to a maximum of one hour of supervised screen time per day for children 24-59 months age, and less than two hours per day for children 5-10 years age”.

25 Jan, 2022 | 09:30h | UTC

Indian Academy of Pediatrics Guidelines on Screen Time and Digital Wellness in Infants, Children and Adolescents

Review: Diagnosis and management of functional neurological disorder.

25 Jan, 2022 | 09:22h | UTC

Diagnosis and management of functional neurological disorder – The BMJ

RCT: Safety and efficacy of Daridorexant in patients with insomnia disorder.

25 Jan, 2022 | 09:15h | UTC

Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials – The Lancet Neurology (link to abstract – $ for full-text)

Perspective: Nervous system consequences of COVID-19.

21 Jan, 2022 | 10:10h | UTC

Nervous system consequences of COVID-19 – Science

Perspective | Post-acute neurological consequences of COVID-19: an unequal burden – “COVID-19 and its neurological consequences particularly burden marginalized communities, and so can only be effectively treated by advancing health equity”.

Review: Counting the neurological cost of COVID-19.

Infection with Covid-19 carries a much higher risk of developing neurological complications than Covid-19 vaccines.

M-A: Frequency of Neurologic Manifestations in COVID-19 – up to one-third of patients (89% hospitalized) experienced at least one neurological manifestation.

Neurological Effects of COVID-19 in Children.

Cohort study: Neurological manifestations of SARS-CoV-2 infection in hospitalized children and adolescents in the UK – “around 1 in 20 of children hospitalized with COVID-19 develop brain or nerve complications linked to the viral infection”.

International Registry: Ischemic and hemorrhagic stroke among critically ill patients with Covid-19.

Short review: Neurological complications of COVID-19.

2 new meta-analysis detail neurologic and psychiatric conditions in COVID-19.

M-A: Encephalitis as Neurological Complication of COVID‐19.

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions Eight out of ten people hospitalized with COVID-19 develop neurological problems – the most common self-reported symptoms included headache (37%) and anosmia or ageusia (26%).

[Preprint] Frequency of neurological manifestations in COVID-19: a systematic review and meta-analysis of 350 studies – up to one-third of COVID-19 patients analyzed in this review, 89% of whom were hospitalized, experienced at least one neurological manifestation

Commentary on Twitter

A new #SciencePerspective discusses the neurological symptoms that accompany #COVID19 and the possible mechanisms that cause them. Read more: https://t.co/WKZpnWlbNc pic.twitter.com/U4ohecaVQd

— Science Magazine (@ScienceMagazine) January 20, 2022

Systematic Review: In people with Alzheimer’s disease and vascular dementia with agitation and psychosis, atypical antipsychotics probably reduce agitation slightly (moderate‐certainty evidence) but probably have a negligible effect on psychosis or risk of any adverse event.

21 Jan, 2022 | 09:50h | UTC

Antipsychotics for agitation and psychosis in people with Alzheimer’s disease and vascular dementia – Cochrane Library

Summary: Do antipsychotic medicines reduce agitated behaviour and psychotic symptoms in people with Alzheimer’s disease and vascular dementia? – Cochrane Library

Meta-analysis of randomized controlled trials: Drug treatment for panic disorder with or without agoraphobia.

20 Jan, 2022 | 09:06h | UTC

Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials – The BMJ

RCT: Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia.

19 Jan, 2022 | 08:11h | UTC

Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study – The Lancet Neurology (link to abstract – $ for full-text)

Commentary: Mixed Salts Oxybate Improves Daytime Performance in Individuals with Idiopathic Hypersomnia – Practical Neurology

RCT: Ketamine induced remission in 46% of patients but was NOT non-inferior to electroconvulsive therapy for the treatment of hospitalized patients with unipolar depression.

16 Jan, 2022 | 23:01h | UTC

Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT) – International Journal of Neuropsychopharmacology

News Release: ECT more effective than ketamine in severe depression – Lund University

Commentary on Twitter

RCT-OL: 63% of inpatients with MDD receiving ECT remitted vs. 46% receiving ketamine infusions (p=0.026). Both ketamine and ECT required a median of 6 sessions to induce remission. Long-lasting AE include persisting amnesia with ECT https://t.co/tvJ0qwUu62 pic.twitter.com/NOQK8Xv8TW

— P𝘧OL (@psychopharmacol) December 12, 2021

Cluster randomized trial: no added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis.

16 Jan, 2022 | 22:59h | UTC

No added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis: a cluster randomised trial – Arthritis & Rheumatism

Systematic Review: Ketamine for the treatment of mental health and substance use disorders.

14 Jan, 2022 | 08:08h | UTC

Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review – BJPsych Open

Commentaries:

Ketamine therapy swiftly reduces depression and suicidal thoughts – University of Exeter

Ketamine May Quickly Ease Tough-to-Treat Depression – HealthDay

M-A: Combined oral contraceptives may improve overall premenstrual symptomatology but are not helpful for premenstrual depressive symptoms.

14 Jan, 2022 | 07:49h | UTC

Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials – American Journal of Obstetrics & Gynecology

Commentary: ‘Optimal’ treatment for premenstrual depressive symptoms remains elusive – Healio (free registration required)

The COVID generation: how is the pandemic affecting kids’ brains?

13 Jan, 2022 | 08:53h | UTC

The COVID generation: how is the pandemic affecting kids’ brains? – Nature

Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.

13 Jan, 2022 | 08:42h | UTC

Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 – The Lancet Psychiatry

Invited Commentary: The true global disease burden of mental illness: still elusive – The Lancet Psychiatry (free registration required)

Phase 2 RCT: Adjunctive ketamine with relapse prevention–based psychological therapy shows promise for the treatment of alcohol use disorder.

12 Jan, 2022 | 08:42h | UTC

Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder – The American Journal of Psychiatry (link to abstract – $ for full-text)

Commentary: People With AUD May Benefit From Combination of Ketamine, Mindfulness Therapy – Psychiatric News Alert

Review | Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop.

11 Jan, 2022 | 02:16h | UTC

Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop – Drug and Therapeutics Bulletin

Commentary from the author on Twitter (thread – click for more)

We were asked to write about balance of harms and benefits of antidepressants based on current knowledge for @DTB_BMJ, a BMJ journal that is famously independent and does not take pharma sponsorship/advertising https://t.co/QCg7Bo1F40 1/n

— Mark Horowitz @markhoro.bsky.social (@markhoro) December 21, 2021

Stay Updated in Your Specialty